30 results on '"Hacker, U. T."'
Search Results
2. Inhibitors of Angiogenesis
3. In vivo Synthesis of Tumor Necrosis Factor-α in Healthy Humans after Live Yellow Fever Vaccination
4. Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer
5. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
6. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
7. Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells
8. Development of Vector Systems for Cancer Gene Therapy: 460
9. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1β after live yellow fever vaccination
10. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) 1β and IL-1 receptor antagonist gene polymorphisms
11. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis
12. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
13. Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
14. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
15. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
16. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
17. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
18. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
19. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
20. The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study.
21. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.
22. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
23. Use of angiopoietin-2 serum levels as a clinical surrogate for vascular normalization under bevacizumab treatment
24. The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-a and nitric oxide
25. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.
26. In Vivo Synthesis of Tumor Necrosis Factor-{alpha} in Healthy Humans after Live Yellow Fever Vaccination
27. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
28. Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells.
29. [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma].
30. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.